60 DEGREES PHARMACEUTICALS, INC. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2026-08-14
- 60 DEGREES PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-06-30 was $0.00.
- 60 DEGREES PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-03-31 was $1.24M, a 27.69% decline year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-12-31 was $0.00.
- 60 DEGREES PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-09-30 was $0.00.
- 60 DEGREES PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2025 was $1.71M.
- 60 DEGREES PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2024 was $0.00.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.24M 10-Q · filed 2026-08-14 | $1.24M derived: sum of 3 quarters · filed 2026-08-14 | $1.24M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.24M 10-Q · filed 2026-05-15 | $1.24M derived: sum of 2 quarters · filed 2026-05-15 | $1.24M derived: sum of 3 quarters · filed 2026-05-15 | $1.24M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $1.71M 10-K · filed 2026-03-30 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $1.71M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.71M 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $1.71M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 |